Obesity Linked to Higher Risk for Adverse Events From Nivolumab
The risk for grade 3 and 4 immune-related adverse events, in particular, was only higher among women with obesity receiving nivolumab monotherapy.
Medscape Medical News
source https://www.medscape.com/viewarticle/985325?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/985325?src=rss
Comments
Post a Comment